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Sufficient evidence points to interleukin (IL)-13 as an important pathological factor in ulcerative colitis and raises hopes to a promising new treatment strategy, [1] [2] [3] . However, the outcome of two recent clinical trials, both published in Gut 2015 suggest otherwise, [4, 5] . A commentary published in the same issue, described these results as crushing the enthusiasm for anti-IL-13 treatment in ulcerative colitis, [6] . In this letter we show evidence that the disease outcome is determined by the type of signalling pathway utilized by IL-13 in mice. Therefore we suggest that directly blocking IL-13 remains a potential treatment strategy for a subset of ulcerative colitis patients that have elevated tissue IL-13 production.
In the first clinical study using Anrukinzumab treatment, which targets the IL-4 receptoralpha (IL-4Rα) and not IL-13 directly, had no effect on improving the clinical response or remission rates of ulcerative colitis patients, [4] . In contrast, although patients treated with Tralokinumab, which blocks IL-13 directly, showed no improved clinical response rate, there was a significantly improved clinical remission rate and partial Mayo score at week 4 in these patients [5] . Here it was suggested that the ability of patients to respond to Tralokinumab depends on baseline levels of colonic mucosal IL-13 and that targeting a sub-group of patients with high levels of mucosal IL-13 may prove to be beneficial in these patients. Highlighting the mode of action of the therapies above, IL-4 and IL-13 both signal through the IL-4Rα. This receptor is part of the type I (IL-4Rα/γc) and type II (IL-4Rα/IL-13α1) receptor complexes. While Anrukinzumab only blocks signalling of IL-13 through IL-4Rα, Tralokinumab blocks IL-13 itself, and would therefore prevent IL-13 from binding any other potential receptors.
Using a mouse model of acute oxazolone-induced colitis [7, 8] , we confirmed that IL-13deficient mice are protected from developing colitis ( Table 1, Microscopic examination showed superficial inflammation scored according to the presence of mononuclear cells, oedema, infiltration of granulocytes, epithelial layer disruption and loss of mucus production. The IL-13-driven pathology can be reverted to protection in IL-4Rα/IL-13-double deficient mice ( Figure 1A -D). Hence, the protection in these mice and the detectable level of IL-13 in IL-4Rα-deficient mice suggests a potential role of IL-13 signalling in mediating colitis, independently of the IL-4Rα.
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Although further investigation is required to confirm a mechanism of the IL-4Rαindependent signalling pathway of IL-13, our results are important to consider when designing new therapeutic strategies against T helper type 2-mediated inflammation.
This data also suggests that attempts to neutralize IL-4Rα may indeed have a detrimental outcome on disease. Furthermore, results from our previous work in an ovalbumininduced dermatitis model suggest that this mechanism may not be limited to ulcerative colitis [11] . In dermatitis, the complete protection of IL-4Rα/IL-13-double deficient but not IL-4Rα mice was associated with a decrease in Extracellular signal-regulated kinases (ERK) phosphorylation of the Mitogen-activated protein kinases (MAPK) signal transduction pathway. This alludes to the possible involvement of IL-13 signalling through the IL-13Rα2, or theoretically an unknown IL-13 receptor. In summary, we conclude that IL-13 signalling is able to drive colitis in the absence of IL-4Rα and suggest that anti-IL-13 treatment but not anti-IL-4Rα treatment strategies could still be beneficial in a subset of ulcerative colitis patients with increased IL-13.
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Induction of colitis by haptenating agent oxazolone
Oxazolone-mediated colitis was induced in BALB/c mice by modifying previously described methods, [6] . Anesthetized mice were sensitized on the shaved abdomen by application of 3% oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one; Sigma-Aldrich) in 100% ethanol (150µl) followed 7 days later by intra-rectal administration of 1% oxazolone in 50% ethanol (150µl). Control mice were sensitized and challenged with ethanol only for all groups. Mice were weighed and monitored daily and killed 3 days post-challenge for immunopathological analyses or 6 days post-challenge for survival studies.
Disease activity index
Oxazolone treated BALB/c mice develop rapid-onset colitis marked by weight loss and distress score. Disease progression was determined as previously described, [6] . Briefly, weight loss was measured as a percentage of starting weight and distress was scored at day 2 post-challenge. Colon length was measured from the anus to the caecum and recorded as an indication of inflammation.
Histological assessment of colitis
Colon sections taken 1 cm from the anus were processed as previously described and stained with haematoxylin and eosin (H&E) for inflammatory cells or Periodic acid-Schiff reagent (PAS) for mucus producing goblet cells. Semi-quantitative histopathological grading of oxazolone-induced colitis was determined as previously described, [6] . Mice were graded on 5 criteria, 1) presence of mononuclear cells, 2) reduced goblet cells, 3) epithelial injury, 4) granulocyte infiltration and 5) oedema. Each criteria were scored from 0-3 and the total score was added resulting in a total additive score of between 0 (no colitis) and 15 (maximal colitis activity). Histology sections were processed and stained by the Department of Surgery, Groote Schuur Hospital. Cells were diluted to 1x10 6 cells/ml and cultured in a 96-well plate in complete IMDM with anti-CD3 (clone: 145-2C11, 10μg/ml) for 48h at 37°C and 5% CO 2 . Supernatants were collected and stored at -80°C.
IL-13 production by mesenteric lymph nodes

Cytokine ELISA
Sandwich ELISAs were performed to determine cytokine levels in cell supernatants.
Maxisorp microtitre plates (Nunc) were coated with purified anti-IL-13 (clone: 38213, 1μg/ml, BD Pharmingen), diluted in phosphate buffered saline (PBS, pH 9.5) and incubated overnight at 4°C. Plates were blocked with milk powder in PBS for 3h at 37°C
and serially diluted standards, purified recombinant IL-13 (BD Pharmingen) was added.
Cell supernatants were added, diluted in ELISA dilution buffer containing bovine serum albumin in PBS and incubated overnight at 4°C. Biotinylated anti-mouse secondary antibody for IL-13 (goat anti-mouse, 0.5μg/ml, BD Pharmingen) was added for 3h at 37°C followed by HRP labelled streptavidin. Subsequently, plates were incubated with TMB Peroxidase Substrate (KPL), the colour reaction stopped with 2M H 2 SO 4 and absorption measured at 450nm. ELISA wash buffer was used to wash plates 4x between each step. 
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